FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

3. November 2009 03:07

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection. [More]

35dc2772-9037-45ed-9229-bb4fde20034b|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Brain, Diabetes, Diabetes Mellitus, Diabetic Ketoacidosis, Diarrhea, Diet, Exenatide, Exercise, Gastroparesis, Headache, Hypoglycemia, Insulin, Metabolism, Metformin, Nausea, Nutrition, Obesity, Pancreatitis, Sulfonylurea, Transplant, Type 1 Diabetes, Type 2 Diabetes, Vomiting, Weight Loss

FDA updates Byetta prescribing information following reports of kidney problems

3. November 2009 01:25

The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes. [More]

cf8f0aae-d887-4434-b1e0-e7ee1522aae9|1|5.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Diabetes, Diarrhea, Endocrinology, Exenatide, Kidney Disease, Metabolism, Nausea, Type 2 Diabetes, Vomiting

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

2. November 2009 01:35

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications. [More]

fdb994b0-b00d-4639-8be3-f979a2f1e325|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Blood Pressure, Diabetes, Exenatide, Metabolism, Obesity, Osteoarthritis, Sleep, Stroke, Type 2 Diabetes

FDA approves an expanded indication for BYETTA injection

31. October 2009 00:31

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. [More]

a2b01897-b631-43e9-80c1-abad4cf86119|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Brain, Diabetes, Diabetes Mellitus, Diabetic Ketoacidosis, Diarrhea, Diet, Exenatide, Exercise, Gastroparesis, Headache, Hypoglycemia, Insulin, Metabolism, Metformin, Nausea, Nutrition, Obesity, Pancreatitis, Sulfonylurea, Transplant, Type 1 Diabetes, Type 2 Diabetes, Vomiting, Weight Loss

Roche discloses the results of first Phase III clinical study using Taspoglutide

29. October 2009 02:45

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research. [More]

a0947d5c-fae4-42d5-9a19-50c5d002c2d6|0|.0

Posted in: Drug Trial News

Tags: Blindness, Diabetes, Diabetes Mellitus, Endocrinology, Exenatide, Insulin, Insulin Glargine, Life Expectancy, Metformin, Nausea, Neurology, Neuropathy, Oncology, Pioglitazone, Renal Failure, Stroke, Vomiting

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

23. October 2009 01:15

New data on patient treatment satisfaction from the LEAD(TM) 6 trial presented on the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide. [More]

234bfc5b-425f-4fb4-9f5c-5795f4dac7f1|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Cholesterol, Diabetes, Diabetes Mellitus, Exenatide, Growth Hormone, Hospital, Insulin, Insulin Glargine, Lipids, Lipoprotein, Metformin, Nausea, Type 2 Diabetes

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

20. October 2009 00:22

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation. [More]

fef8ee77-658d-47ae-a76b-ca24f5e817e5|1|5.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Blood Pressure, Brain, Diabetes, Diet, Dyslipidemia, Estrogen, Exenatide, Leptin, Metabolism, Obesity, Osteoarthritis, Sleep, Stroke, Type 2 Diabetes, Weight Loss

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

17. September 2009 07:47

Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of exenatide. [More]

ac696cf9-0cc4-4589-ae02-4aeada3346b0|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Diabetes, Drug Delivery, Exenatide, Hepatitis C, Metformin, Type 2 Diabetes

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

11. September 2009 05:58

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology. [More]

edb8b57a-0332-4111-b366-b6c9b4da968d|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Antibody, Biotechnology, Cancer, Diabetes, Exenatide, Insulin, Metabolism, Monoclonal Antibody, Obesity, Oncology

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

18. August 2009 02:30

SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production. [More]

37592acf-20cf-4d60-bc1e-ba26e3fb6381|0|.0

Posted in: Pharmaceutical News

Tags: Amino Acid, Biotechnology, Diabetes, Endocrinology, Exenatide, Growth Hormone, Type 2 Diabetes

NDA for Exenatide once weekly accepted for FDA review

7. July 2009 21:55

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA). [More]

4a14aa64-21fd-4a7b-b4f4-511de5586863|0|.0

Posted in: Pharmaceutical News

Tags: Diabetes, Exenatide, Hypoglycemia, Metformin, New Drug Application (NDA), Sulfonylurea, Thiazolidinediones, Type 2 Diabetes

Diabetes drug exenatide promotes weight loss when added to diet and exercise

13. June 2009 20:53

In combination with diet and exercise, the diabetes drug exenatide helped nondiabetic, obese individuals lose over three times more weight than those receiving a placebo, or dummy treatment, for 6 months. [More]

ee8a14a0-b6cb-4159-ac60-b320ee87f4a9|0|.0

Posted in: Medical Research News

Tags: Diabetes, Diet, Endocrinology, Exenatide, Exercise, Glucose Metabolism, Obesity

Novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight

9. June 2009 07:53

New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide. [More]

f87f858d-cbf6-4ff9-be21-728355c1228c|2|3.0

Posted in: Drug Trial News

Tags: Exenatide, Glucose Metabolism, Syncria (albiglutide), Type 2 Diabetes

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

8. December 2008 21:25

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control. [More]

769c1ba6-5066-4f69-b7b4-37bef1a51c9e|0|.0

Posted in: Pharmaceutical News

Tags: Abdominal Pain, Brain, Diabetes, Diarrhea, Exenatide, Hypoglycemia, Insulin, Metformin, Nausea, Nutrition, Sulfonylurea, Type 2 Diabetes, Vomiting, Weight Loss

Expensive new diabetes drugs don't necessarily produce better outcomes

28. October 2008 01:16

The annual cost of prescription diabetes drugs nearly doubled to $12.5 billion between 2001 and 2007, according to a study by researchers at the Stanford University School of Medicine and the University of Chicago. The researchers say the findings raise questions about whether the higher cost actually translates into improved care and better outcomes. [More]

66ee034e-9ec6-4eb4-b93c-9c3231fa14e4|0|.0

Posted in: Pharmaceutical News

Tags: Cancer, Cholesterol, Diabetes, Exenatide, Generic Drug, Insulin, Metformin, Obesity, Osteoporosis

Free!

Recent Comments

Twitter

Information

Exenatide News and Research

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA updates Byetta prescribing information following reports of kidney problems

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

FDA approves an expanded indication for BYETTA injection

Roche discloses the results of first Phase III clinical study using Taspoglutide

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

NDA for Exenatide once weekly accepted for FDA review

Diabetes drug exenatide promotes weight loss when added to diet and exercise

Novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Expensive new diabetes drugs don't necessarily produce better outcomes

Recent Articles

Free!

Recent Comments

Twitter

Information

Exenatide News and Research

Medical News Cloud

Recent Articles